|
|
2929, 7th Street, Suite 120
Berkeley, CA 94710 USA
phone:510-549-5500
fax:510-549-5501
|
|
| Symbol |
Private |
| Founded |
2004 |
| Employees |
|
|
|
| www.aerovance.com
|
|
| Research Sector |
Biotech Specialty Pharma |
|
 |
| Summary Description |
| Biotherapeutics for asthma, cystic fibrosis, chronic obstructive pulmonary disease and eczema. |
|
| Management |
| Mark L. Perry, President & Chief Executive Officer; David A. Happel, Executive Vice President, Chief Commercial Officer; Robert W. Kuhn, Ph.D., Senior Vice President, Chief Technology Officer; Tunde Otulana, M.D., Senior Vice President, Chief Medical Officer; Anthony M. Rimac, C.P.A., Vice President, Chief Financial Officer |
| |
|
|
| |
|
| Keywords |
| inflammatory, aeroderm, pulmonary, respiratory, allergic |
|
|
|
| Description |
|
Aerovance is focused on developing and commercializing biotherapeutics for asthma, cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD) and eczema. |
|
| Products / Services |
The lead products are human recombinant proteins: AEROVANT, an IL-4 and IL-13 receptor antagonist currently in Phase 2a studies for asthma; AEROLYTIC, a serine protease inhibitor currently in Phase 1 for CF; and AERODERM', and IL-4 and IL-13 receptor antagonist entering Phase 2a studies for eczema.
|
|
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members